Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guohong Han

Showing results (131-140 of 200) with videos related to

Pageof 20
Sort By:
Journal of Gastroenterology and Hepatology|December 7, 2011
Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective studyXingshun Qi, Cheng Zhang, Guohong Han, et al.
Journal of Gastroenterology|April 10, 2026
Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort studyFeng Shi, Zhenwei Peng, Shanshan Lian, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 20, 2016
Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis PatientsXingshun Qi, Guohong Han, Chun Ye, et al.
European Journal of Gastroenterology & Hepatology|September 7, 2018
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosisKryssia I Rodriguez-Castro, Alessandro Vitale, Mariangela Fadin, et al.
Journal of Gastroenterology and Hepatology|November 12, 2019
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational studyJiahao Fan, Qiuhe Wang, Bohan Luo, et al.
International Journal of Cancer|September 30, 2016
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenibWenjun Wang, Wei Bai, Enxin Wang, et al.
Digestive Diseases and Sciences|July 29, 2025
Irradiation Stents Versus Conventional Stents for Unresectable Malignant Hilar Biliary Obstruction: A Retrospective StudyMenghao Li, Jiang Jin, Jing Niu, et al.
Gastroenterology|September 27, 2020
Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient DataOana Nicoară-Farcău, Guohong Han, Marika Rudler, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 20, 2017
Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate CandidatesEnxin Wang, Lei Liu, Dongdong Xia, et al.
Radiology|July 7, 2017
Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with CirrhosisYong Lv, Chuangye He, Zhengyu Wang, et al.
Pageof 20

Showing results (131-140 of 200) with videos related to

Sort By:
Pageof 20
Journal of Gastroenterology and Hepatology|December 7, 2011
Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective studyXingshun Qi, Cheng Zhang, Guohong Han, et al.
Journal of Gastroenterology|April 10, 2026
Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort studyFeng Shi, Zhenwei Peng, Shanshan Lian, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|July 20, 2016
Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis PatientsXingshun Qi, Guohong Han, Chun Ye, et al.
European Journal of Gastroenterology & Hepatology|September 7, 2018
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosisKryssia I Rodriguez-Castro, Alessandro Vitale, Mariangela Fadin, et al.
Journal of Gastroenterology and Hepatology|November 12, 2019
Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: A hospital-based observational studyJiahao Fan, Qiuhe Wang, Bohan Luo, et al.
International Journal of Cancer|September 30, 2016
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenibWenjun Wang, Wei Bai, Enxin Wang, et al.
Digestive Diseases and Sciences|July 29, 2025
Irradiation Stents Versus Conventional Stents for Unresectable Malignant Hilar Biliary Obstruction: A Retrospective StudyMenghao Li, Jiang Jin, Jing Niu, et al.
Gastroenterology|September 27, 2020
Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient DataOana Nicoară-Farcău, Guohong Han, Marika Rudler, et al.
Journal of Vascular and Interventional Radiology : JVIR|April 20, 2017
Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate CandidatesEnxin Wang, Lei Liu, Dongdong Xia, et al.
Radiology|July 7, 2017
Association of Nonmalignant Portal Vein Thrombosis and Outcomes after Transjugular Intrahepatic Portosystemic Shunt in Patients with CirrhosisYong Lv, Chuangye He, Zhengyu Wang, et al.
Pageof 20